MGMT, O-6-methylguanine-DNA methyltransferase, 4255

N. diseases: 444; N. variants: 24
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0334588
Disease: Giant Cell Glioblastoma
Giant Cell Glioblastoma 		0.510 Biomarker disease ORPHANET A study of clinico-pathological parameters and O⁶-methylguanine DNA methyltransferase (MGMT) promoter methylation status in the prognostication of gliosarcoma. 22380407 2012
CUI: C0334588
Disease: Giant Cell Glioblastoma
Giant Cell Glioblastoma 		0.510 GeneticVariation disease BEFREE Our data indicate, that in addition to the histological and immunohistochemical evaluation, investigation of MGMT promoter methylation and in particular BRAF V600E mutations represent reliable additional tools to sustain differentiation of gcGBM from PXA on a molecular basis. 27253461 2016
CUI: C0334588
Disease: Giant Cell Glioblastoma
Giant Cell Glioblastoma 		0.510 Biomarker disease ORPHANET O6-methylguanine DNA methyltransferase status determined by promoter methylation and immunohistochemistry in gliosarcoma and their clinical implications. 20556478 2011
CUI: C0334588
Disease: Giant Cell Glioblastoma
Giant Cell Glioblastoma 		0.510 Biomarker disease CTD_human MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma. 20131314 2010
CUI: C0334588
Disease: Giant Cell Glioblastoma
Giant Cell Glioblastoma 		0.510 Biomarker disease CTD_human Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor. 22162573 2012
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.400 Biomarker disease BEFREE O6-Methylguanine-DNA methyltransferase is a novel negative effector of invasion in glioblastoma multiforme. 22986464 2012
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.400 PosttranslationalModification disease BEFREE The RT-MSP assay that we developed in-house is a robust clinical detection method for the heterogeneous process of MGMT promoter methylation in glioblastoma. 28967952 2017
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.400 AlteredExpression disease BEFREE Human brain tumors that were highly resistant to ACNU, such as glioblastoma Gbl1 and metastatic brain tumor Col1 with SD10 values (microM) of above 100, expressed markedly increased amounts of 0.95 kb MGMT mRNA. 1518162 1992
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.400 GeneticVariation disease BEFREE Methylation of the MGMT promoter correlated with better PFS and OS after GKS for recurrent GBM. 28536992 2017
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.400 PosttranslationalModification disease BEFREE Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. 22139906 2012
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.400 GeneticVariation disease BEFREE Combined Therapy Sensitivity Index Based on a 13-Gene Signature Predicts Prognosis for IDH Wild-type and MGMT Promoter Unmethylated Glioblastoma Patients. 31632497 2019
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.400 Biomarker disease BEFREE Consistent with this reasoning, we found that the MGMT-expressing glioblastoma cell lines exhibiting an unmethylated MGMT promoter that were pretreated with decitabine became significantly more sensitive to temozolomide. 24568970 2014
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.400 Biomarker disease BEFREE MGMT is one of the important markers in glioblastomas as it not only predicts response to therapy but may also be used as an independent prognostic marker. 30444735 2019
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.400 PosttranslationalModification disease BEFREE MGMT promoter hypermethylation was detected in 38.7% of glioblastoma patients. 31701343 2020
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.400 PosttranslationalModification disease BEFREE Methylation of the O(6)-methylguanine-DNA methyltransferase (MGMT) gene promoter is a favorable prognostic factor in glioblastoma patients. 22390413 2012
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.400 AlteredExpression disease BEFREE Interestingly, inhibitors of DNA methylation and histone deacetylation failed to increase MGMT protein levels in the transformed astrocyte cells as well as cultured glioblastoma cell lines, whereas the treatment partially restored mRNA levels. 17547775 2007
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.400 PosttranslationalModification disease BEFREE In fact, first steps have been undertaken in supplementing classical histopathological diagnosis by the use of molecular tests, such as MGMT promoter hypermethylation in glioblastomas or detection of losses of chromosome arms 1p and 19q in oligodendroglial tumors. 19333441 2009
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.400 AlteredExpression disease BEFREE Temozolomide (TMZ), as the first-line chemotherapy agent used in patients with glioblastoma, has demonstrated different effects in patients due to the expression of O6-methylguanine-DNA methyltransferase (MGMT) which is able to repair the DNA lesions induced by TMZ. 29151909 2017
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.400 Biomarker disease BEFREE While the importance of MGMT methylation is well established, we demonstrate that the combination of MGMT(methylated)/IDH1(+ve) is associated with considerably longer OS and PFS in this series of chemoradiotherapy-treated glioblastoma tumours. 27526690 2016
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.400 GeneticVariation disease BEFREE There is no consensus recommendation regarding the best available treatment for patients over age 70 with glioblastoma; however, multiple studies have shown molecular characterization of glioblastoma in this group-particularly MGMT promoter methylation status-to be valuable in treatment decision making. 28620898 2017
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.400 GeneticVariation disease BEFREE The pathological diagnosis was glioblastoma (GBM) with unmethylated O-6-methylguanine-DNA methyltransferase promoter and wild isocitrate dehydrogenase 1 gene. 23053494 2013
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.400 PosttranslationalModification disease BEFREE The utilization of MGMT promoter methylation testing in United States hospitals for glioblastoma and its impact on prognosis. 29483008 2018
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.400 PosttranslationalModification disease BEFREE This new NRG-GBM-RPA model improves outcome stratification over both the current RTOG RPA model and MGMT promoter methylation, respectively, for patients with GBM treated with radiation and temozolomide and was biologically validated in an independent data set. 28097324 2017
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.400 Biomarker disease BEFREE Epigallocatechin Gallate Preferentially Inhibits O<sup>6</sup>-Methylguanine DNA-Methyltransferase Expression in Glioblastoma Cells Rather than in Nontumor Glial Cells. 30558449 2019
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.400 PosttranslationalModification disease BEFREE MGMT hypermethylation and MDR system in glioblastoma cancer stem cells. 22798502 2012